The short answer: Most people notice less hunger within the first few weeks, but the scale moves slowly at first because the starting dose is only a first step. In the largest Zepbound (tirzepatide) trial, average weight loss reached roughly 15% to 22% of body weight at 72 weeks, depending on the dose, and it
Bottom Line In a 42-week, placebo-controlled Phase 2 trial of 485 adults, a once-weekly injection called petrelintide produced average weight loss of up to about 10% (up to 10.2% when everyone assigned to the drug is counted, up to 10.7% in people while they stayed on it), versus about 1.4% to 1.7% with placebo. It
